Should I Buy BIVI? BIVI 2026 Analysis

Should You Buy BioVie Inc (BIVI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.130

1 Day change

6.60%

52 Week Range

20.300

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the broader trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no proprietary buy signals today.
The pre-market pop to ~1.29 (+8.4%) is pushing into resistance (R1 ~1.281, R2 ~1.326), which makes the current level a poor chase-entry for an impatient buyer.
With no recent news/catalysts and weak fundamentals (no revenue; large losses), the move looks more like short-term volatility than the start of a durable uptrend.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), indicating the stock is still in a downtrend despite today’s bounce.
Momentum: MACD histogram is slightly positive (0.00594) but “positively contracting,” suggesting upside momentum is weakening rather than accelerating.
RSI: RSI_6 ~44.5 (neutral-to-soft), not showing strong oversold bounce conditions.
Levels: Pivot ~1.208. Price ~1.29 pre-market is above pivot and testing resistance R1 ~1.281 (already reached/cleared) and near R2 ~1.326; support sits at S1 ~1.136 then S2 ~1.091.
Probabilistic pattern read: Similar-pattern stats lean negative near-term (next day ~-1.1%, next week ~-3.53%) with a more mixed 1-month expectation (+4.97%), reinforcing “not a great buy right now” for immediate gratification.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Reported historical volatility is extremely high (~98.53), consistent with a highly speculative, fast-moving name.
Put/call ratios shown as 0 and missing open interest/volume fields imply options data is sparse/inconclusive; sentiment read from options is not reliable from the provided dataset.

Technical Summary

Sell

Buy

Positive Catalysts

if buyers follow through.

Neutral/Negative Catalysts

- Primary trend remains bearish (stacked moving averages down), so rallies are technically “counter-trend” until structure improves.
- No news in the last week: today’s move lacks an identified catalyst, increasing the chance of a fade after the open.
- Financial profile remains weak: revenue is 0 and losses remain large; EPS worsened sharply YoY.
- Trading trends: hedge funds and insiders are neutral (no supportive accumulation signal).
- Congress/influential trading: no recent data available (no confirmatory tailwind).

Financial Performance

Latest quarter: 2026/Q1.
Revenue: 0 (0.00% YoY change) — no operating revenue base indicated.
Net income: -5,131,101 (improved ~14.61% YoY, i.e., loss narrowed).
EPS: -0.98 (down ~86.00% YoY), indicating per-share performance deteriorated despite the net loss improvement line item.
Gross margin: 0 (0.00% YoY), consistent with no revenue generation in the quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so no identifiable recent upgrades/downgrades or target revisions can be cited.
Wall Street pro/con view cannot be validated from the dataset; with no coverage signals included here, the actionable stance from provided data stays driven by technicals (bearish trend) and fundamentals (no revenue).

Analyst Rating

Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.060

Low

Averages

High

Current: 1.060

Low

Averages

High

Brookline

NULL -> Buy

maintain

$6 -> $12

AI Analysis

2025-08-29

Reason

Brookline

Price Target

$6 -> $12

AI Analysis

2025-08-29

maintain

NULL -> Buy

Reason

Brookline adjusted the firm's price target on BioVie to $12 from $6 and keeps a Buy rating on the shares. The firm cites the company's recent 1-for-10 reverse stock split for the target adjustment. It believes BioVie's cash position provides a runway through fiscal 2026.

BIVI Should I Buy

BIVI Should I Buy

Should You Buy BioVie Inc (BIVI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch